We should consider both the treatment effects and adverse effects of autologous hematopoietic stem cell transplantation (AHSCT) on multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD). Articles exploring the effect and safety of AHSCT in the treatment of MS and NMOSD and published before December 2019 were identified from the following databases (PubMed, Web of Science, Medline, EMBASE, Cochrane and Google Scholar). The study used STATA 13.0 software to compute the efficacy outcomes. Finally, the meta-analysis included 27 studies (including 1626 MS and 31 NMOSD patients). Regarding the effect of AHSCT on MS, the computed PFS was 74%. Subgroup analyses showed that intermediate-intensity regimen caused PFS 73%. Low-intensity regimen resulted in PFS 85%. High-intensity regimen resulted in PFS 58%. Subgroup analyses indicated that relapsing remitting MS (RRMS), primary progressive MS (PPMS) and secondary progressive MS (SPMS) patients showed PFS 81%, 78% and 60%, respectively. Computed transplant-related mortality (TRM) in MS was 1%. Regarding effect of AHSCT on NMOSD, the computed PFS and TRM was 76% and 0%, respectively. In conclusion, the study supported that AHSCT showed long-term effect on MS and NMOSD patients with a high safety. Low- and intermediate-intensity regimens and RRMS patients showed optimal benefit from AHSCT.

我们应该同时考虑自体造血干细胞移植（AHSCT）对多发性硬化症（MS）和视神经脊髓炎谱系疾病（NMOSD）的治疗效果和不良反应。从以下数据库（PubMed、Web of Science、Medline、EMBASE、Cochrane 和 Google Scholar）中确定了探索 AHSCT 在治疗 MS 和 NMOSD 中的效果和安全性并在 2019 年 12 月之前发表的文章。该研究使用 STATA 13.0 软件计算疗效结果。最后，荟萃分析包括 27 项研究（包括 1626 名 MS 和 31 名 NMOSD 患者）。关于 AHSCT 对 MS 的影响，计算的 PFS 为 74%。亚组分析显示，中等强度方案可导致 73% 的 PFS。低强度方案的 PFS 为 85%。高强度方案的 PFS 为 58%。亚组分析表明，复发缓解型 MS (RRMS)、原发性进展型 MS (PPMS) 和继发进展型 MS (SPMS) 患者的 PFS 分别为 81%、78% 和 60%。MS 中计算的移植相关死亡率 (TRM) 为 1%。关于 AHSCT 对 NMOSD 的影响，计算的 PFS 和 TRM 分别为 76% 和 0%。总之，该研究支持 AHSCT 对 MS 和 NMOSD 患者具有高安全性的长期影响。低强度和中强度方案和 RRMS 患者从 AHSCT 中显示出最佳益处。该研究支持AHSCT对MS和NMOSD患者具有高安全性的长期效果。低强度和中强度方案和 RRMS 患者从 AHSCT 中显示出最佳益处。该研究支持AHSCT对MS和NMOSD患者具有高安全性的长期效果。低强度和中强度方案和 RRMS 患者从 AHSCT 中显示出最佳益处。